-Anna- schreef:
GTC Biotherapeutics is Unaware of Any Reason for Unusual Trading Activity
Wednesday February 8, 3:33 pm ET
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Feb. 8, 2006--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced that it is unaware of any reason for the unusual trading activity today in its common stock. GTC does not expect to have any new announcement regarding its ATryn® submission to the European Medicines Agency before the conclusion of the meeting of the Committee for Medicinal Products for Human Use (CHMP) which takes place from February 20 through February 23.
ADVERTISEMENT
ATryn® is GTC's recombinant form of human antithrombin. A Market Authorization Application (MAA) is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. ATryn® is also in a pivotal phase III study for the prevention of thromboembolic events in patients with hereditary antithrombin deficiency who are undergoing high-risk procedures, such as surgery or childbirth. GTC anticipates using the results from this clinical study to prepare a Biologics License Application for the United States Food and Drug Administration.
Antithrombin is a protein in human plasma that has anticoagulant and anti-inflammatory properties.